Bristol-Myers to promote Caforio to CEO post; other appointments

21 January 2015

US pharma major Bristol-Myers Squibb (NYSE: BMY) yesterday announced a number of leadership changes approved by its board of directors and effective at the close of the annual shareholders’ meeting on May 5.

Giovanni Caforio, aged 50, will become chief executive officer of the company.
Current CEO Lamberto Andreotti, aged 64, will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3.

James Cornelius, 71, has chosen not to stand for re-election as non-executive chairman and will retire from the board.
Togo West Jr, 72, will become the lead independent director on the company’s board.

Dr Caforio has been on the Bristol-Myers board since last year. He joined the company in 2000 as an executive in Italy following a medical affairs role at Abbott Laboratories.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK